Pfizer looks forward to oncology potential

Pfizer is “excited” about breaking into oncology biosimilars in the US, given the oncology market’s “different dynamics” that typically result in higher and faster biosimilar uptake, especially in light of the US-based player’s struggles to gain a meaningful US market share for its Inflectra (infliximab-dyyb) autoimmune diseases biosimilar.

“We see different dynamics in that the duration of treatment [for oncology] is shorter, therefore you’re going to get new...